EPO Patent Bulletin - Pharma (A61K)

Novel Compounds - Inflazome Limited EP3759102A1

The European Patent Office published patent application EP3759102A1 for Inflazome Limited, titled 'Novel Compounds.' The patent covers heterocyclic compounds classified under C07D with pharmaceutical applications (A61K, A61P). The application designates all EU member states plus several additional European countries.

Novel Pyrazole Compounds for Inflammatory Disease Treatment

The European Patent Office has published patent EP3759103A1, granting Inflazome Limited intellectual property protection for novel pyrazole-derived compounds. Inventors include David Miller, Jimmy Van Wiltenburg, and Matthew Cooper. The compounds are classified under A61K 31/415 with therapeutic applications targeting inflammatory diseases.

Pfizer CD70 CAR Chimeric Antigen Receptor Patent Application EP3746483A1

The European Patent Office published Pfizer Inc.'s patent application EP3746483A1 for chimeric antigen receptors targeting CD70. The application (A1 publication with European search report) covers compositions and methods for CD70-targeting CARs with 11 named inventors including Srivatsa Srinivasan and Barbra Johnson Sasu. The application designates all EU member states plus other EPC contracting states.

Piperidinyl Aryloxy Propanamides and Propanoates Patent EP3759094A1

The European Patent Office published patent application EP3759094A1 for Takeda Pharmaceutical Company Limited covering piperidinyl-3-(aryloxy)propanamides and propanoates compounds. The patent application includes therapeutic indications for depression (A61P 25/24), CNS disorders (A61P 25/28), and psychiatric disorders (A61P 25/18). The application designates multiple European states including Germany, France, United Kingdom, Italy, Spain, and others.

Mature Virus-Like Particles of Flaviviruses Vaccine

The EPO published patent application EP3976768A1, filed by Chiang Mai University and NSTDA, covering mature virus-like particles (VLPs) of flaviviruses for use as vaccines. The invention relates to the production of immunogenic VLP compositions and methods for preventing flavivirus infections. The patent designates 33 European states including major markets such as DE, FR, GB, IT, and ES.

Base-Modified Cytidine Nucleotides for Leukemia Therapy (EP3810140A1)

The European Patent Office published patent application EP3810140A1 for Medivir Aktiebolag covering base-modified cytidine nucleotides for leukemia therapy. The application includes IPC classifications for A61K 31/506 (pyrimidine derivatives), C07D 405/04 (heterocyclic compounds), and A61P 35/02 (antineoplastic agents). The patent designates all EPO member states including AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR.

Solid Form Composition for Use in Treatment of Extraoesophageal Symptoms of Gastric Reflux

The European Patent Office published patent application EP3752202A1 filed by Drugs Minerals and Generics Italia S.R.L. for a solid dosage form composition intended for treating extraoesophageal symptoms of gastric reflux. The application, filed with inventor Luigi Mercuri, designates multiple EU member states including DE, FR, GB, IT, ES, NL, and 24 others. This publication establishes a priority date for the claimed pharmaceutical composition.

Amgen Antigen Binding Proteins Targeting Beta-Klotho and FGF Receptors

The European Patent Office granted Amgen Inc. Patent EP3760642A1 covering human antigen binding proteins that bind beta-Klotho, FGF receptors, and complexes thereof. The patent covers therapeutic applications including treatment of metabolic conditions (A61P 3/04). The patent is designated for all 31 European states including DE, FR, GB, IT, ES, NL, SE, and 21 others.

D3 Receptor Agonist Compounds; Methods of Preparation; Intermediates Thereof; and Methods of Use Thereof

EPO published patent application EP3953350A1 for D3 receptor agonist compounds filed by the United States Department of Health and Human Services. The patent covers specific chemical compounds, methods of preparation, intermediates thereof, and methods of therapeutic use.

Bifunctional BTK Degrading Compounds Via Ubiquitin Proteasome Pathway

The European Patent Office published patent EP3924350A1, granted to Nurix Therapeutics, Inc., covering bifunctional compounds for degrading BTK via the ubiquitin proteasome pathway. The patent application includes six IPC classifications spanning pharmaceutical compositions and therapeutic methods. Protection extends across 31 designated European states including major markets.

UPAR Targeting Peptide for Peroperative Optical Imaging of Invasive Cancer

The EPO published patent application EP3733215A1 for Fluoguide A/S, covering a UPAR targeting peptide for peroperative optical imaging of invasive cancer. The patent names Andreas Kjaer and Morten Persson as inventors and includes designations across multiple European member states including DE, FR, GB, IT, ES, NL, and others. This publication grants intellectual property protection for the novel peptide composition and its diagnostic use in cancer surgery.

European Patent for Kava-Derived Therapeutic Compounds and Methods of Use Thereof

EPO granted patent EP3068416A1 to Kuality Herbceutics LLC and 9 named inventors for kava-derived therapeutic compounds and methods of use. The invention is classified under IPC codes A61K 31/12, A61K 31/353, A61K 31/366 (therapeutic compounds) and A61P 35/00 (cancer treatment). The patent is designated in 36 European states including Germany, France, UK, Italy, Spain, Netherlands, Belgium, Austria, and Switzerland.

Engineered High-Affinity Human T Cell Receptors - EP3071594A1

The European Patent Office published patent application EP3071594A1 for engineered high-affinity human T cell receptors, filed by the Board of Trustees of the University of Illinois. The invention relates to engineered high-affinity human T cell receptors (TCRs) with applications in cancer immunotherapy. The application is classified under C07K 14/725, A61K 38/17, and A61P 35/00, with designation extending to all EU member states plus other European countries.

Integrin Alpha10 Patent for Aggressive Cancer Treatment

The European Patent Office published patent application EP3956360A1 for Integrin Alpha10 compositions and methods for treating aggressive cancer forms. Applicant Targinta AB seeks protection across 37 designated European states. The patent covers anti-integrin alpha10 antibodies and therapeutic applications for cancer treatment.

Lonza Ltd Patents Larch Tree Arabinogalactan-Polyphenol Composition

The European Patent Office published patent application EP2638914A1 filed by Lonza Ltd, covering a composition comprising arabinogalactan and polyphenols derived from larch trees. The application, filed by inventors Freitas and Rodriguez, is classified under IPC codes A61K 36/13, A61P 31/00, and A61P 31/12, indicating therapeutic anti-infective applications. The patent designates all EU member states and additional European countries.

Neurotrophin Binding Protein p75NTR for Osteoarthritis Treatment - Patent EP3169347A1

The European Patent Office published patent application EP3169347A1 on April 8, 2026, covering neurotrophin binding protein p75NTR for use in treating osteoarthritis. Applicant Levicept Limited, invented by Simon Westbrook, received European patent protection covering A61K therapeutic compositions. The patent designates all EPC contracting states including AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, and TR.

DLL3 Targeting Chimeric Antigen Receptors and Binding Agents

EPO published patent application EP3930744A1 by Allogene Therapeutics Inc. and Pfizer Inc. for DLL3 targeting chimeric antigen receptors (CARs) and binding agents. The application classified under A61K 39/00, A61P 35/00, and C07K 16/28 covers therapeutic compositions targeting DLL3 for cancer treatment. The patent designates 31 European states including Germany, France, the United Kingdom, Italy, Spain, and other EU member states.

Methods of Treating Locally Advanced or Metastatic Breast Cancers Using PD-1 Axis Binding Antagonists and Taxanes

The European Patent Office published patent application EP3310815A1, filed by F. Hoffmann-La Roche AG, covering methods of treating locally advanced or metastatic breast cancers using PD-1 axis binding antagonists in combination with taxanes. Inventor is Daniel S. Chen. The publication includes IPC classifications covering therapeutic antibodies, antineoplastic compositions, and designated states for national phase entry.

PD-1 Antibodies, Nanjing Legend Biotech, 8th Apr

PD-1 Antibodies, Nanjing Legend Biotech, 8th Apr

Phosphoantigen Prodrug Compounds

The European Patent Office granted patent EP3818064A1 for phosphoantigen prodrug compounds to University College Cardiff Consultants Ltd. and University of Birmingham. The patent covers novel chemical compounds with applications in immunology and oncology, classified under IPC C07F 9/44 and A61K 31/664. The patent is valid in 44 designated contracting states across Europe.

TNF Inhibitor for Gastrointestinal Disease Treatment, EP3810095A1

The EPO published patent application EP3810095A1 for BT Bidco, Inc., covering a TNF inhibitor formulation for treating gastrointestinal diseases. The patent application was published under IPC classifications A61K 9/22, A61K 31/436, and A61K 48/00. The application designates all EU member states plus other EPC contracting states including CH, GB, LI, MC, NO, TR, and IS.

Hydrocortisone for Treatment of Mastitis in Non-Human Mammals, EP3829591A1

The European Patent Office published Patent Application EP3829591A1 for VIRBAC covering hydrocortisone formulations for treating mastitis in non-human mammals. The application names inventors HAVRILECK Bertrand, JASMIN Pierre, and MCGAHIE David with IPC classifications in A61K therapeutic preparations. The designated states cover EU contracting states including AT, BE, DE, ES, FR, GB, IT, NL, PL, and others.

Compounds, Compositions, Methods, and Uses for Treating Cancer and Immunological Disorders

The European Patent Office granted Patent EP3820533A2 to IL-2RX, Inc. covering novel compounds and compositions for treating cancer and immunological disorders. The patent application, filed by inventors Soares and Hurt, was published April 8, 2026 under IPC classifications A61K 47/64, A61K 47/65, A61P 35/00, and A61P 37/02. The patent is designated for all EU member states and extended territories.

Thiocycloheptyne Derivatives and Their Use

The EPO published European patent application EP3820858A1 for thiocycloheptyne derivatives and their pharmaceutical use, filed by Cristal Delivery B.V. The patent covers thiocycloheptyne compound compositions and their therapeutic applications under IPC classification A61K. The patent is validated in all designated EU contracting states including Germany, France, the United Kingdom, Italy, Spain, and 24 other jurisdictions.

Polyglutamated Antifolates and Uses Thereof (EP3496757A1)

The European Patent Office published patent application EP3496757A1 for polyglutamated antifolates and their therapeutic uses, filed by L.E.A.F Holdings Group LLC. The patent covers compositions for treating cancer and inflammatory conditions. The application was published April 8, 2026, designating 36 European states including Germany, France, the United Kingdom, Italy, Spain, and other EU member states. No compliance deadlines or penalties are specified.

Fibrous Dosage Form EP3500242A1

The European Patent Office published patent application EP3500242A1 titled 'Fibrous Dosage Form' on April 8, 2026. The patent application, filed by applicant Aron H. Blaesi with inventors Blaesi and Nannaji Saka, covers pharmaceutical dosage formulations classified under IPC A61K. The application designates multiple European member states for patent protection.

Immunoglobulin antibody against RSV prefusion F protein, published 8th Apr

Immunoglobulin antibody against RSV prefusion F protein, published 8th Apr

PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES

The European Patent Office granted Patent EP3244930A1 to the University of Southern California on April 8, 2026. The patent covers pharmaceutical compositions comprising POH derivatives for therapeutic applications including cancer treatment. The patent is designated across 38 European member states including DE, FR, GB, IT, ES, NL, BE, and others.

Bi-Specific Cancer Treatment Constructs with Different Epitope Binding

The European Patent Office published patent application EP3484516A1 assigned to Fred Hutchinson Cancer Center on April 8, 2026. The patent covers bi-specific binding domain constructs with different epitope binding properties for treating cancer. The technology falls under IPC classifications A61K 39/395, C07K 16/28, and C12N 15/09, with designated states covering major European markets.

TLR4 Antagonist Patent for Multiple Myeloma Treatment EP3558323A1

The European Patent Office granted patent EP3558323A1 for specific TLR4 antagonists in the treatment of multiple myeloma. The patent applicants include Etablissement Français du Sang, CNRS, Université Paul Sabatier Toulouse III, and INSERM. Designated states cover all EU member states plus other EPC contracting states.

Novel Recombinant Protein UK114 in Stable Polymer Form for Tumour Treatment

The European Patent Office granted Patent EP3554639A1 to Alberto Bartorelli Cusani for a novel recombinant protein UK114 in stable polymer form designed for the treatment or prevention of malignant solid and systemic tumours. The patent covers pharmaceutical compositions containing the recombinant protein and methods of treatment. The patent is classified under A61K 38/50 and related pharmaceutical categories.

Bispecific Anti-TRAILR2 and Anti-CDH17 Binding Molecules for Cancer Treatment - EP3559040A2

The EPO published patent application EP3559040A2, filed by Boehringer Ingelheim International GmbH, covering bispecific binding molecules that simultaneously target TRAILR2 (TNF-related apoptosis-inducing ligand receptor 2) and CDH17 (cadherin 17) for the treatment of cancer. The patent application was published on April 8, 2026 and is classified under IPC categories C07K 16/28, A61K 39/395, A61P 35/00, and C12N 15/62. The application designates all EPO contracting states covering major European pharmaceutical markets.

EP3283091A1 - Berry Extraction Method Using Alkaline Magnesium Compound

The European Patent Office granted Patent EP3283091A1 to inventor Reijonen, Mika Tapio. The patent covers a method of extracting berries or fruits using an alkaline magnesium compound for use in pharmaceutical, herbal, nutritional, or cosmetic ingredients. The patent is valid in 38 designated European states.

Shiseido Skin Glow Evaluation Method Patent EP3219302A1

The European Patent Office published Shiseido Company Ltd.'s patent application EP3219302A1 covering methods for evaluating skin glow, methods for examining skin glow improving agents, and skin glow improving compositions. The patent application was published on April 8, 2026, designating 37 European states including DE, FR, GB, IT, ES, and others. The application includes inventors Masuda Yuji, Yagi Eiichiro, and Kuwahara Tomohiro.

Long-Acting Injectable Formulations Comprising an Isoxazoline Active Agent (EP3261617A1)

The European Patent Office published European patent application EP3261617A1 for Boehringer Ingelheim Vetmedica GmbH covering long-acting injectable formulations comprising isoxazoline active agents. The application classifies under IPC codes A61K 31/422, A61K 31/42, A61K 9/00, and A01N 43/80. The application designates 36 European contracting states including Germany, France, United Kingdom, Italy, Spain, and other EU member states.

Pharmaceutical Composition Comprising Lipoic Acid and Taurine as Osmoprotective Agent

The EPO granted Patent EP3297733A1 to Dulcis Health Science for a pharmaceutical composition combining lipoic acid and taurine as an osmoprotective agent. The patent, published April 8, 2026, lists inventors Claret, Martine, Claret, Claude, and Chatard-Baptist, Caroline, with designations covering all 31 European Patent Convention member states.

Cinnamyl Alcohol Derivative for Appetite Reduction

The European Patent Office published application EP3474833A1 for Symrise AG covering a cinnamyl alcohol derivative for reducing appetite and generating satiety. The invention lists Veronika Somoza, Barbara Lieder, Katrin Geissler, Joachim Hans, Kathrin Langer, Jakob Peter Ley, and Sabine Widder as inventors. The application classifies under A61K 31/015, A61K 31/185, and A61K 31/215. Validated designated states include DE, FR, GB, IT, ES, NL, and other EPC contracting states.

Artificial Sweat Composition, EP3355853A1, Apr 08

Artificial Sweat Composition, EP3355853A1, Apr 08